Pain scoring in cancer patients
Not Applicable
- Conditions
- Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site
- Registration Number
- CTRI/2024/04/066243
- Lead Sponsor
- Jawaharlal Nehru Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Cancer patients requiring chemotherapy treatment and having pain
Being followed by the hospital oncology department
Exclusion Criteria
Cancer patients with pain in the terminal stage of the disease
Mentally retarded patients
Patients with cognitive dysfunction
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage and proportion of cancer patients undergoing chemotherapy reporting sensorial, emotional, evaluative and miscellaneous characteristics of pain by McGill Pain QuestionnaireTimepoint: At the baseline
- Secondary Outcome Measures
Name Time Method Socio demographic and clinical determinants of painTimepoint: At the baseline.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cancer-related pain exacerbation during chemotherapy in CTRI/2024/04/066243?
How does the McGill Pain Questionnaire - NI compare to other pain assessment tools in oncology?
Are there specific biomarkers associated with pain severity in neoplasm patients with D499 classification?
What are the most common adverse events reported in cancer pain studies using observational designs like CTRI/2024/04/066243?
How effective are standard-of-care analgesics versus novel pain management strategies in D499 chemotherapy patients?